SCHEMBL23218359

SCHEMBL23218359

CCOC(=O)Cc1cccc(C#N)c1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 2/20 0.48
ALDH1A1 P00352 4/20 0.45
GAA P10253 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TSHR P16473 1/20 0.44
MAPT P10636 2/20 0.44
PKM P14618 1/20 0.43
KDM4E B2RXH2 2/20 0.41
CYP2C9 P11712 1/20 0.41
KMT2A Q03164 1/20 0.40
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
NFKB1 P19838 1/20 0.39
STAT1 P42224 1/20 0.39
RAB9A P51151 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30676655 1.00 NLRP3 (0.48) NLRP3ALDH1A1GAAL3MBTL1TSHR
SCHEMBL7219075 0.86 NLRP3 (0.55) NLRP3ALDH1A1GAAL3MBTL1TSHR
SCHEMBL29852731 0.85 ALDH1A1 (0.46) NLRP3ALDH1A1GAAL3MBTL1TSHR
SCHEMBL5568979 0.84 NLRP3 (0.47) NLRP3ALDH1A1GAAL3MBTL1TSHR
SCHEMBL21438124 0.80 PKM (0.51) NLRP3ALDH1A1MAPTPKMKDM4E
SCHEMBL29853174 0.80 PKM (0.51) NLRP3ALDH1A1MAPTPKMKDM4E
SCHEMBL29122112 0.79 NLRP3 (0.48) NLRP3ALDH1A1GAAL3MBTL1MAPT
SCHEMBL11230027 0.79 GABRA1 (0.61) ALDH1A1GAAL3MBTL1TSHRRAB9A
SCHEMBL6034698 0.78 AKR1B1 (0.50) ALDH1A1GAAL3MBTL1TSHRMAPT
SCHEMBL11224969 0.77 CHEK1 (0.50) NLRP3ALDH1A1PKMKMT2ACYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
CN-117120419-A KLK5 bicyclic heteroaromatic inhibitors 拜奥克里斯特制药公司 2023-11-24 CN disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 KLK5, KLK1, KLKB1 NLRP3 1428/4885ALDH1A1 1532/4885GAA 193/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB NLRP3 1028/4885ALDH1A1 2667/4885GAA 2438/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB NLRP3 279/4885ALDH1A1 3142/4885GAA 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.